Breaking News

You are here » Indian-Commodity  :  Equity & Shares  :  Laurus Labs advances on receiving nod for Tenofovir Disoproxil Fumarate Tablets

01-Dec2017

Laurus Labs advances on receiving nod for Tenofovir Disoproxil Fumarate Tablets

Laurus Labs is currently trading at Rs. 538.05, up by 14.15 points or 2.70% from its previous closing of Rs. 523.90 on the BSE.

The scrip opened at Rs. 550.00 and has touched a high and low of Rs. 550.00 and Rs. 535.70 respectively. So far 14,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 634.00 on 12-Jun-2017 and a 52 week low of Rs. 453.00 on 26-Dec-2016.

Last one week high and low of the scrip stood at Rs. 550.00 and Rs. 514.20 respectively. The current market cap of the company is Rs. 5,715.00 crore.

The promoter and public held 30.56% and 69.44% stake in the company, respectively.

Laurus Labs has received its maiden tentative approval from United States Food and Drug Administration (USFDA) for Tenofovir Disoproxil Fumarate Tablets 300mg. Tenofovir Disoproxil Fumarate Tablets 300mg is therapeutically equivalent to VIREAD Tablets 300mg of Gilead Science (GILEAD). Tenofovir Disoproxil Fumarate Tablets 300mg is used for treatment of HIV-1 infection in adults and paediatric patients 2 years of age and older.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.



Related News

View all news

Viaan Industries inches up on getting nod to acquire 50% stake in Avalance Technology

Viaan Industries is currently trading at Rs. 7.25, up by 0.04 points or 0.55% from its previous closing of Rs. 7.21 on the BSE.The scrip opened at Rs. 7.25 and has touched a high and low of Rs. 7.25 and......

SAIL gains on the BSE

Steel Authority of India is currently trading at Rs. 54.05, up by 0.45 points or 0.84% from its previous closing of Rs. 53.60 on the BSE.The scrip opened at Rs. 54.35 and has touched a high and low of......

Dr. Reddy's Laboratories gains on launching B2B customer service portal 'XCEED'

Dr. Reddys Laboratories is currently trading at Rs. 2696.00, up by 26.55 points or 0.99% from its previous closing of Rs. 2669.45 on the BSE.The scrip opened at Rs. 2669.65 and has touched a high and low......

Top News

View all news

RIL's telecom arm terminates agreement with Reliance Communications

Reliance Industries' (RIL) telecom arm -- Reliance Jio Infocomm (Jio) has terminated Master Agreement and Spectrum Trading Agreement executed between the company and Reliance Communications and its affiliates......

Hotel Leela Venture signs binding agreement with Brookfield

Hotel Leela Venture (HLVL) has entered into a binding agreement with a Brookfield Asset Management sponsored private real estate fund, to sell by way of slump sale, four owned Leela hotels located at Bangalore,......

Dr. Reddy's Laboratories launches B2B customer service portal 'XCEED'

Dr. Reddy's Laboratories has launched B2B customer service portal 'XCEED' to increase the operational efficiency. The portal is focused on meeting the growing demand for the company's portfolio of generic......